Private equity (PE) firm ChrysCapital is looking to exit its investment in pharmaceutical firm Eris Lifesciences through an initial public offering (IPO) and has initiated talks for the same, said three people aware of the development.
The move comes after ChrysCapital’s talks to exit through a secondary stake sale to other private equity firms.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com